Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity

Bibliography

• LEONARDI A, POGGESI E, TADDEI C et al.: In vitro calcium-antagonistic activity of lercanidipine and its enantiomers. J. Cardiovasc. Pharmacol (1997) 29\(Suppl. 1):S10–S18.
   Google Scholar
• GUARNERI L, ANGELICO P, IBBA M et al: Pharma-cological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine. Arzneim Forsch/Drug Res. (1996) 46:15–24.
   PubMed Web of Science ®Google Scholar
• •An evaluation of the preclinical data with lercanidipine.
   Google Scholar
• CERBAI E, BARBIERI M, MUGELLI A: Electrophysio-logical study on lercanidipine and its enantiomers. J. Cardiovasc. Pharmacol (1997) 29\(Suppl. 1):S1–S9.
   Google Scholar
• TESTA R, LEONARDI A, TAJANA A, RISCASSI E, MAGLIOCCA R, SARTANI A: Lercanidipine REC 15/2375: a novel 1,4-dihydropyridine calcium antagonist for hypertension. Cardiovasc. Drug Reviews (1997) 15:187–219.
   Google Scholar
• ••A valuable overview of the clinical and preclinical pharma-cology of lecercanidipine.
   Google Scholar
• GUARNERI L, SIRONI G, ANGENCO P et al.: In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers. J. Cardiovasc. Pharmacol. (1997) 29 (Suppl. 1):S25–S32.
   Google Scholar
• LICHTLEN PR, HUGENHOLTZ PG, RAFFLENBLEU W,HECKER H, JOST S, DECKERS JW: Retardation of angiographic progression of coronary artery disease by nifedipine. Results on the International Trial on Antiatherosclerotic Therapy (INTACT). Lancet (1990) 335:1109–1113.
   Google Scholar
• SOWERS JR: Calcium channel blockers and atheroscle-rosis. Am. J. Kid. Dis. (1990) 16:3–9.
   PubMed Web of Science ®Google Scholar
• WEINSTEIN DB, HEIDER JG: Antiatherogenic properties of calcium-antagonists. Am. J. Cardiol. (1987) 59:163B–172B.
   Google Scholar
• CORSINI A, BONFATTI M, QUARATO P et al: Effect of thenew calcium antagonist lercanidipine and its enanti-omers in the migration and proliferation of arterial myocytes. J. Cardiovasc. Pharmacol (1996) 28:687–694.
   PubMed Web of Science ®Google Scholar
• CATAPANO A, BELLOMO G: Personal communication.
   Google Scholar
• ROSSONI G, BERNAREGGI M, DE GENNARO COLONNA V,POLVANI G, BERTI F: Lercanidipine protects the heart from low-flow ischaemia damage and antagonizes the vasopressor activity of endothelin-1. J. Cardiovasc. Pharmacol. (1997) 29\(Suppl. 1):S41–S47.
   Google Scholar
• BORASO A, BERNOCCHI P, BENIGNO M et al.: Time-dependence of the cardioprotective effects of lercanidipine. J. Cardiovasc. Pharmacol (1997) 29\(Suppl. 1):S69–S77.
   Google Scholar
• CARGNONI A, BENIGNO M, FERRARI F et al.: Effects oflercanidipine and its enantiomers on ischemia and reperfusion. J. Cardiovasc. Pharmacol. (1997) 29\(Suppl. 1):S48–562.
   Google Scholar
• BERNOCCHI P, CECONI C, PEDERSINI P, BORASO A, CURELLO S, FERRARI R: Effects of lercanidipine on Fe2±-induced mitochondrial lipid peroxidation. J. Cardiovasc. Pharmacol. (1997) 29\(Suppl. 1):S63–S68.
   Google Scholar
• KAUDER WF, WATTS JA: Antioxidant properties of dihydropyridines in isolated rat hearts. Comparison of nisoldipine, nispoldipine enantiomers, and nifedipine. Biochem. Pharmacol. (1996) 51:811–819.
   Google Scholar
• UNTERBERG C, BUCHWALD AB, MINDEL L, KREUZER H:Oxygen free radical damage of isolated cardiomyo-cytes: Comparative protective effect of radical scaven-gers and calcium antagonists. Basic Res. Cardiol. (1992) 87:148–160.
   PubMed Web of Science ®Google Scholar
• SIRONI G, MONTAGNA E, GRETO L, BIANCHI G, LEONARDI A, TESTA R: Antihypertensive effects of lercanidipine in experimental hypertensive rats and dogs. Arzneim Forsch/Drug Res. (1996) 46:145–152.
   PubMed Web of Science ®Google Scholar
• SIRONI G, COLOMBO D, GRETO L, TESTA R, LEONARDI A:Antihypertensive activity of lercanidipine and its enantiomers in animal models. J. Cardiovasc. Pharmacol. (1997) 29 (Suppl. 1):S33–S40.
   Google Scholar
• SIRONI G, MONTAGNA E, GRETO L, LEONARDI A, TESTAR: Hemodynamic effects of lercanidipine in anaesthe-tized open-chest dogs. Arzneim Forsch/Drug Res. (1996) 46:256–261.
   PubMed Web of Science ®Google Scholar
• TESTA R, RIMOLDI 0, SIRONI G, LEONARDI A, MALLIANIA: Hemodynamic effects and power spectral analysis of heart rate and arterial pressure variabilities induced by lercanidipine and its enantiomers in conscious dogs. J. Cardiovasc. Pharmacol (1997) 29 (Suppl. 1):S78–S85.
   Google Scholar
• BIANCHI G, PASSONI A, GRIFFINI PL: Effects of a newcalcium antagonist, Rec 15/2375, on cardiac contrac-tility of conscious rabbits. Pharmacol Res. (1989) 21:193–200.
   PubMed Web of Science ®Google Scholar
• SOMA MR, NATALI M, DONETTI E et al.: Effect of lercanidipine and its (R)-enantiomer on atheroscle-rotic lesions induced in hypercholesterolaemic rabbits. Br. J. Pharmacol. (1998) 125:1471–1476.
   PubMed Web of Science ®Google Scholar
• ••Documented evidence of the fact that theanti-atherosclerotic activity of lercanidipine is not dependent upon its calcium channel blocking properties.
   Google Scholar
• FARINA P, TARGA G, LEONI B, TAJANA A: Pharmacoki- netics of lercanidipine in animals. I. Absorption, plasma concentrations, and excretion after admini-stration of [14C] lercanidipine to rats, mice, rabbits and dogs. J. Cardiovasc. Pharmacol. (1997) 29\(Supp1.1):S86–S96.
   Google Scholar
• FARINA P, TARGA G, LEONI B, TAJANA A: Pharmacoki-netics of lercanidipine in animals. Distribution to and elimination from organs and tissues after administra-tion of [14C] lercanidipine to rats and dogs. Whole-body autoradiography, biliary excretion and entero-hepatic circulation and biotransformation in rats. J. Cardiovasc. Pharmacol (1997) 29\(Suppl. 1):S97–S108.
   Google Scholar
• HERBETTE LG, VECCHIARELLI M, LEONARDI A: Lercanidipine: Short plasma half-life, long duration of action 'A molecular model to rationalize its pharma-cokinetic properties'. J. Cardiovasc. Pharmacol (1997) 29\(Suppl. 1):S19–S24.
   Google Scholar
• ••An important appraisal of the molecular basis of the longduration of action of lercanidipine.
   Google Scholar
• BARCHIELLI M, DOLFINI E, FARINA P et al: Clinicalpharmacokinetics of lercanidipine. J. Cardiovasc. Pharmacol. (1997) 29\(Suppl. 2):S1–S15.
   Google Scholar
• OMBONI SANCHETTI A: Antihypertensive efficacy of lercanidipine 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambula-tory blood pressure. J. Hypertension (1998) 16:1831–1838.
   Google Scholar
• •A definitive assessment of the efficacy and duration of action of lercanidipine.
   Google Scholar
• RIMOLDI E, LUMINA C, FRIEDRICH J et al.: Evaluation ofthe once daily activity of REC 15/2375 in the treatment of hypertension. Curr. Ther. Res. (1992) 52:196–201.
   Web of Science ®Google Scholar
• RIMOLDI E, LUMINA C, GIUNTA L, MOSCATELLI P, GATTOE: Evaluation of the efficacy and tolerability of two different formulations of lercanidipine versus placebo after once daily administration in mild to moderate hypertensive patients. Curr. Ther. Res. (1993) 54:248–253.
   Web of Science ®Google Scholar
• RIMOLDI E, LUMINA C, SEGA R, LIBRETTI A: Efficacy and tolerability of lercanidipine once a day versus placebo in mild to moderate arterial hypertension. Acta Therapeutica (1994) 20:23–31.
   Google Scholar
• CIRCO A: Active dose findings for lercanidipine in a double-blind, placebo-controlled design in patients with mild to moderate hypertension. J. Cardiovasc. Pharmacol. (1997) 29\(Suppl. 2):S22–S26.
   Google Scholar
• AMBROSIONI E, CIRCO A: Activity of lercanidipineadministered in single and repeated doses once daily as monitored over 24 h in patients with mild to moderate essential hypertension. J. Cardiovasc. Pharmacol. (1997) 29\(Suppl. 2):S16–S20.
   Google Scholar
• PATERNA S, LICATA A, ARNONE S, COTTONE C, CORRAOS, LICATA G: Lercanidipine in two different dosage regimens as a sole treatment for severe essential hypertension. J. Cardiovasc. Pharmacol. (1997) 29\(Suppl. 2):S51–S54.
   Google Scholar
• NINCI MA, MAGLIOCCA R, MALLIANI A: Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J. Cardiovasc. Pharmacol. (1997) 29\(Suppl. 2):S41–S45.
   Google Scholar
• CAFIERO M, GIASI M: Long-term (12 month) treatmentwith lercanidipine in patients with mild to moderate hypertension. J. Cardiovasc. Pharmacol. (1997) 9\(Suppl. 2):S46–S50.
   Google Scholar
• POLICICCHIO D, MAGLIOCCA R, MALLIANI A: Efficacyand tolerability of lercanidipine in patients with mild to moderate hypertension. A comparative study with slow-release nifedipine. J. Cardiovasc. Pharmacol. (1997) 29\(Suppl. 2):S32–S36.
   Google Scholar
• RENGO F, ROMIS L: Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension. J. Cardiovasc. Pharmacol. (1997) 29\(Suppl. 2):S55–S59.
   Google Scholar
• MORISCO C, TRIMARCO B: Efficacy and tolerability oflercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double-blind controlled study. J. Cardiovasc. Pharmacol. (1997) 29\(Suppl. 2):S27–S31.
   Google Scholar
• BARBAGALLO SANGIORGI G, PUTIGNANO E, CALCARA L,BARBAGALLO M: Efficacy and tolerability of lercanidipine vs. captopril in patients with mild to moderate hypertension in a double-blind controlled study. J. Cardiovasc. Pharmacol. (1997) 29\(Suppl. 2):S37–S40.
   Google Scholar
• FURBERG CD, PATSY BM, MEYER JV: Niledipine,dose-related increase in mortality in patients with coronary heart disease. Circulation (1995) 92:1326–1331.
   PubMed Web of Science ®Google Scholar
• STAESSEN J, FAGARD R, THUS L et al.: Randomiseddouble-blind comparison of placebo and active treatment in older patients with isolated systolic hypertension. Lancet (1997) 350:747–764.
   Google Scholar
• OHANSSON L, ZANCHETTI A, CARRUTHERS SG for the HOT study group: Effects of intense blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet (1998) 351:1755–1762.
   PubMed Web of Science ®Google Scholar
• ZANCHETTI A, BIANCHI L, BOZZA M for the ItalianNifedipine GITS Study Group: Antihypertensive effects of nifedipine GITS on clinic and ambulatory blood pressures in essential hypertensives. High Blood Pressure (1994) 3:45–56.
   Google Scholar
• MEREDITH PA, ELLIOTT HL: Amlodipine: clinicalrelevance of a unique pharmacokinetic profile. J. Cardiovasc. Pharmacol. (1993) 22 (Suppl. A):S6–S8.
   Google Scholar